Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Add To Watchlist

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > RE: Off Topic

View:

Post by Red~One on Aug 16, 2022 10:06am

RE: Off Topic

CLAS History
Santa Maria Petroleum Inc. and Kalytera Therapeutics, Inc. Provide Update Regarding Proposed Merger
V.CLAS | November 29, 2016
TORONTO, ONTARIO--(Marketwired - Nov. 29, 2016) –
Andy Salzman - Chief Executive Officer and Director
Robert Farrell - Chief Financial Officer, Chief Operating Officer, Director
Kalytera Announces Management Changes and Expansion of Leadership Team
V.CLAS | June 22, 2017
today announced that Andrew L. Salzman, M.D., who previously served as Kalytera’s Chief Executive Officer and Chief Medical Officer, and as a member of Kalytera’s Board of Directors, will be leaving the Company, effective June 21, 2017. Robert Farrell, J.D., President and CFO of Kalytera, will assume the role of interim Chief Executive Officer (“CEO”).

155